Search company, investor...

Founded Year




Total Raised


Market Cap


Stock Price


About Transgenomic

Transgenomic (NASDAQ:TBIO) is a global biotechnology company that advances personalized medicine in oncology and inherited diseases via its products and services for automated high-sensitivity genetic variation and mutation analysis. Their offerings include systems, products, discovery, and laboratory testing services to the academic and medical research, clinical laboratory, and biopharmaceutical markets in the fields of pharmacogenomics and personalized medicine. Their flagship product is ICE COLD-PCR, which enables use of liquid biopsies for mutation detection.

Headquarters Location

12325 Emmet Street

Omaha, Nebraska, 68164,

United States




Transgenomic Patents

Transgenomic has filed 7 patents.

patents chart

Application Date

Grant Date


Related Topics




Molecular biology, Polymerase chain reaction, Biotechnology, Molecular biology techniques, Transcription factors


Application Date


Grant Date



Related Topics

Molecular biology, Polymerase chain reaction, Biotechnology, Molecular biology techniques, Transcription factors



Latest Transgenomic News

Global Stem Cell Partnering Terms and Agreements 2010-2022: Featuring Celltex Therapeutics, Promega, Transgenomic & More

Jul 14, 2022

News provided by Share this article Share this article The Global Stem Cell Partnering Terms and Agreements 2010-2022 report provides comprehensive understanding and unprecedented access to the stem cell partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in stem cell partnering Partnering agreement structure Average deal terms for stem cells The report provides a detailed understanding and analysis of how and why companies enter Stem Cell partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes. This report provides details of the latest Stem Cell agreements announced in the life sciences since 2010. The report takes the reader through a comprehensive review Stem Cell deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Stem Cell partnering deals. The report presents financial deal term values for Stem Cell deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals. The middle section of the report explores the leading dealmakers in the Stem Cell partnering field; both the leading deal values and most active Stem Cell dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market. One of the key highlights of the report is that over 650 online deal records of actual Stem Cell deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not. In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Stem Cell technologies and products. Key benefits In-depth understanding of Stem Cell deal trends since 2010 Access to headline, upfront, milestone and royalty data Detailed access to actual Stem Cell contracts entered into by leading biopharma companies Identify most active Stem Cell dealmakers since 2010 Insight into terms included in a Stem Cell partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies Report scope Global Stem Cell Partnering Terms and Agreements 2010-2022 is intended to provide the reader with an in-depth understanding and access to Stem Cell trends and structure of deals entered into by leading companies worldwide. Stem Cell Partnering Terms and Agreements includes: Trends in Stem Cell dealmaking in the biopharma industry since 2010 Access to headline, upfront, milestone and royalty data Access to Stem Cell contract documents Leading Stem Cell deals by value since 2010 Most active Stem Cell dealmakers since 2010. Key Topics Covered:

Transgenomic Frequently Asked Questions (FAQ)

  • When was Transgenomic founded?

    Transgenomic was founded in 1997.

  • Where is Transgenomic's headquarters?

    Transgenomic's headquarters is located at 12325 Emmet Street, Omaha.

  • What is Transgenomic's latest funding round?

    Transgenomic's latest funding round is PIPE.

  • How much did Transgenomic raise?

    Transgenomic raised a total of $10M.

  • Who are the investors of Transgenomic?

    Investors of Transgenomic include Dorset Management, Knott Partners, Endeavor Capital Management, SF Capital Group, LBi International and 6 more.

  • Who are Transgenomic's competitors?

    Competitors of Transgenomic include Gliknik, Immunetrics, BioDelivery Sciences International, Flexion Therapeutics, OpGen and 7 more.


Compare Transgenomic to Competitors

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company focused on providing business intelligence in the pharmaceutical and biologic drugs sector. The company's main services include offering insights on life cycle management, brand erosion, generic entry, biosimilars, patents, sales, litigation, and more, all related to pharmaceutical and biologic drugs. The company primarily serves the biopharmaceutical industry. It is based in Troy, New York.


SideroGen, Inc. is focused on the development and manufacture of biomolecule purification products for applications in the fields of forensic science and clinical genomics. These products will be developed for processing very small samples, common to forensic science and cancer diagnostics. The core technology for these products is based on inert ferro-ceramic, paramagnetic particles of compositions that are specifically designed to be compatible with downstream DNA and protein analysis. This technology and its uses are exclusively owned and were developed by SideroGen, Inc.

Axela Biosensors

Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.

CAPE Technologies

CAPE Technologies specializes in high performance immunotechnology for environmental testing. The company offers a practical immunoassay kit for dioxin and furan analysis, designed to provide rapid and sensitive screening with a reasonable cost. The primary sectors served include environmental monitoring and regulatory compliance industries. It is based in South Portland, Maine.


microLAN is a biotech company specializing in water quality monitoring systems. The company offers a range of online monitors that detect algae, bacteria, and chemical contamination in water, providing early warning signals for water pollution. These systems are designed to monitor water quality in real-time, allowing for immediate action in case of contamination. It is based in Netherlands.


Kelaroo is a software company specializing in solutions for the pharmaceutical and biotechnology industries. The company offers a suite of proprietary software designed to simplify and streamline chemical reagent inventory management, synthesis outsourcing processes, and bioinformatics discovery programs. Kelaroo's products are tailored to enhance functionality with simple, yet powerful interfaces, without the need for extensive product training. It was founded in 2000 and is based in Solana Beach, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.